title: Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada.
abstract: The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG(®) compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG(®) were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG(®) resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG(®) is expected to be the dominant treatment option over FFP in Canada.
authors.affiliation: MAPI Consultancy, De Molen 84, 3995 AX Houten, The Netherlands. Electronic address: ehuisman@mapigroup.com.
authors.forename: Eline L
authors.initials: EL
authors.lastname: Huisman
authors.affiliation: MAPI Consultancy, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: Margreet C
authors.initials: MC
authors.lastname: van Eerd
authors.affiliation: MAPI Consultancy, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: J N Mario
authors.initials: JN
authors.lastname: Ouwens
authors.affiliation: MAPI Consultancy, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: Maria A
authors.initials: MA
authors.lastname: de Peuter
mesh_terms: D000328:Adult; D016913:Blood Component Transfusion; D002170:Canada; D003365:Costs and Cost Analysis; D003902:Detergents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018803:Models, Economic; D011788:Quality of Life; D012997:Solvents
chemical_list: D003902:Detergents; D012997:Solvents
keywords: Canada; Cost-effectiveness analysis; Fresh-frozen plasma; OctaplasLG(®); Transfusion